基于肽的治疗：一种有前景的癌症疗法。
Peptide-Based Treatment: A Promising Cancer Therapy.
作者信息
Xiao Yu-Feng, Jie Meng-Meng, Li Bo-Sheng, Hu Chang-Jiang, Xie Rui, Tang Bo, Yang Shi-Ming
机构信息
Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
出版信息
J Immunol Res. 2015;2015:761820. doi: 10.1155/2015/761820. Epub 2015 Oct 19.
Abstract
Many new therapies are currently being used to treat cancer. Among these new methods, chemotherapy based on peptides has been of great interest due to the unique advantages of peptides, such as a low molecular weight, the ability to specifically target tumor cells, and low toxicity in normal tissues. In treating cancer, peptide-based chemotherapy can be mainly divided into three types, peptide-alone therapy, peptide vaccines, and peptide-conjugated nanomaterials. Peptide-alone therapy may specifically enhance the immune system's response to kill tumor cells. Peptide-based vaccines have been used in advanced cancers to improve patients' overall survival. Additionally, the combination of peptides with nanomaterials expands the therapeutic ability of peptides to treat cancer by enhancing drug delivery and sensitivity. In this review, we mainly focus on the new advances in the application of peptides in treating cancer in recent years, including diagnosis, treatment, and prognosis.
摘要
目前，许多新疗法正用于治疗癌症。在这些新方法中，基于肽的化疗因其独特优势而备受关注，比如分子量低、能够特异性靶向肿瘤细胞以及对正常组织毒性低。在癌症治疗中，基于肽的化疗主要可分为三种类型：单独肽疗法、肽疫苗和肽偶联纳米材料。单独肽疗法可能会特异性增强免疫系统对肿瘤细胞的杀伤反应。基于肽的疫苗已用于晚期癌症以提高患者的总生存率。此外，肽与纳米材料的结合通过增强药物递送和敏感性扩展了肽治疗癌症的能力。在本综述中，我们主要关注近年来肽在癌症治疗应用中的新进展，包括诊断、治疗和预后。
相似文献
1
Peptide-Based Treatment: A Promising Cancer Therapy.基于肽的治疗：一种有前景的癌症疗法。
J Immunol Res. 2015;2015:761820. doi: 10.1155/2015/761820. Epub 2015 Oct 19.
2
Composite peptide-based vaccines for cancer immunotherapy (Review).用于癌症免疫治疗的基于复合肽的疫苗（综述）
Int J Mol Med. 2015 Jan;35(1):17-23. doi: 10.3892/ijmm.2014.2000. Epub 2014 Nov 12.
3
Peptide-based vaccines for cancer therapy.用于癌症治疗的肽基疫苗。
Hum Vaccin Immunother. 2014;10(11):3175-8. doi: 10.4161/hv.29418.
4
Current developments with peptide-based human tumor vaccines.基于肽的人类肿瘤疫苗的最新进展。
Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e.
5
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.合成长肽个性化新抗原疫苗接种：最新进展与未来展望。
Theranostics. 2020 May 15;10(13):6011-6023. doi: 10.7150/thno.38742. eCollection 2020.
6
Antitumor vaccination using peptide based vaccines.使用基于肽的疫苗进行抗肿瘤疫苗接种。
Immunol Lett. 2000 Sep 15;74(1):27-34. doi: 10.1016/s0165-2478(00)00245-5.
7
Cancer Neoantigens and Applications for Immunotherapy.癌症新抗原与免疫治疗应用。
Clin Cancer Res. 2016 Feb 15;22(4):807-12. doi: 10.1158/1078-0432.CCR-14-3175. Epub 2015 Oct 29.
8
Development of tumour peptide vaccines: From universalization to personalization.肿瘤肽疫苗的研发：从普适化到个体化。
Scand J Immunol. 2020 Jun;91(6):e12875. doi: 10.1111/sji.12875. Epub 2020 Mar 10.
9
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?基于肽的疫苗的癌症免疫疗法：我们取得了哪些成果？我们将何去何从？
J Natl Cancer Inst. 2002 Jun 5;94(11):805-18. doi: 10.1093/jnci/94.11.805.
10
Cancer immunotherapy: moving forward with peptide T cell vaccines.癌症免疫疗法：用肽 T 细胞疫苗推进。
Curr Opin Immunol. 2017 Aug;47:57-63. doi: 10.1016/j.coi.2017.07.003. Epub 2017 Jul 19.
引用本文的文献
1
Advanced Nanomaterials Functionalized with Metal Complexes for Cancer Therapy: From Drug Loading to Targeted Cellular Response.用于癌症治疗的金属配合物功能化先进纳米材料：从药物负载到靶向细胞反应
Pharmaceuticals (Basel). 2025 Jul 3;18(7):999. doi: 10.3390/ph18070999.
2
Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity.细胞质中连接蛋白43与微管的相互作用促进胶质母细胞瘤干细胞样细胞的维持和致瘤性。
Cell Death Dis. 2025 May 16;16(1):388. doi: 10.1038/s41419-025-07514-2.
3
Polymeric microneedle advancements in macromolecule drug delivery: current trends, challenges, and future perspectives.高分子药物递送中聚合物微针的进展：当前趋势、挑战及未来展望。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 17. doi: 10.1007/s00210-025-04117-8.
4
Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies.表观遗传学奇迹：通过前沿的基于表观遗传学的药物策略探索结直肠癌治疗前景
Clin Epigenetics. 2025 Feb 22;17(1):34. doi: 10.1186/s13148-025-01844-w.
5
Development of a Novel Peptide with RGD Tumor Homing Motif: Evaluation of its Anticancer Potential in Hepatocellular Carcinoma and Colon Cancer Cells.一种具有RGD肿瘤归巢基序的新型肽的研发：评估其在肝癌和结肠癌细胞中的抗癌潜力
Recent Pat Biotechnol. 2025;19(2):128-141. doi: 10.2174/0118722083300452240315035722.
6
Peptide hemolytic activity analysis using visual data mining of similarity-based complex networks.使用基于相似性的复杂网络的可视化数据挖掘分析肽的溶血活性。
NPJ Syst Biol Appl. 2024 Oct 4;10(1):115. doi: 10.1038/s41540-024-00429-2.
7
ACP-CapsPred: an explainable computational framework for identification and functional prediction of anticancer peptides based on capsule network.ACP-CapsPred：一种基于胶囊网络的用于识别和抗癌肽功能预测的可解释计算框架。
Brief Bioinform. 2024 Jul 25;25(5). doi: 10.1093/bib/bbae460.
8
Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective.肿瘤归巢肽作为基于磁性的递药系统的关键组成部分：最新进展和药物经济学视角。
Int J Mol Sci. 2024 Jun 5;25(11):6219. doi: 10.3390/ijms25116219.
9
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.用于肺癌免疫治疗的新抗原鉴定及基于树突状细胞的疫苗
Vaccines (Basel). 2024 May 5;12(5):498. doi: 10.3390/vaccines12050498.
10
Membrane-Active Peptides and Their Potential Biomedical Application.膜活性肽及其潜在的生物医学应用。
Pharmaceutics. 2023 Aug 6;15(8):2091. doi: 10.3390/pharmaceutics15082091.
本文引用的文献
1
Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.尿组织金属蛋白酶抑制剂-1（TIMP-1）和基质金属蛋白酶-2（MMP-2）水平可检测胰腺恶性肿瘤的存在。
Br J Cancer. 2014 Oct 28;111(9):1772-9. doi: 10.1038/bjc.2014.462. Epub 2014 Aug 19.
2
A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.一项评估接种hTERT隐蔽肽的HLA-A2(+)非小细胞肺癌患者临床和免疫反应的II期试验。
Lung Cancer. 2014 Oct;86(1):59-66. doi: 10.1016/j.lungcan.2014.07.018. Epub 2014 Aug 5.
3
Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients.RGS6表达降低与胰腺癌患者的不良预后相关。
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4120-7. eCollection 2014.
4
Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles.通过CXCR4拮抗剂偶联的聚乳酸-羟基乙酸共聚物纳米颗粒将阿霉素靶向递送至A549肺癌细胞。
Eur J Pharm Biopharm. 2014 Oct;88(2):529-38. doi: 10.1016/j.ejpb.2014.06.020. Epub 2014 Aug 10.
5
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.巨噬细胞抑制细胞因子1（MIC-1/GDF15）作为胰腺导管腺癌一种新型的血清诊断生物标志物。
BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.
6
Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.用ErbB-2肽进行疫苗接种可预防癌症干细胞扩增，并抑制MMTV-PyMT转基因小鼠自发肿瘤的发展。
Breast Cancer Res Treat. 2014 Aug;147(1):69-80. doi: 10.1007/s10549-014-3086-4. Epub 2014 Aug 8.
7
Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.使用包裹在融合性DOTAP阳离子脂质体中的p5 HER-2/neu衍生肽与CpG-ODN共同给药有效诱导抗肿瘤免疫。
Immunol Lett. 2014 Nov;162(1 Pt A):87-93. doi: 10.1016/j.imlet.2014.07.008. Epub 2014 Jul 30.
8
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.预测结直肠癌五种治疗性表位肽疫苗接种结局的生物标志物。
Anticancer Res. 2014 Aug;34(8):4201-5.
9
Peptides with in vitro anti-tumor activity from the venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae).来自东部绿曼巴蛇（Dendroaspis angusticeps，眼镜蛇科）毒液的具有体外抗肿瘤活性的肽。
J Venom Res. 2014 Jun 19;5:16-21. eCollection 2014.
10
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.转移性复发性三阴性乳腺癌患者个性化肽疫苗接种的可行性研究
Breast Cancer Res. 2014 Jul 3;16(4):R70. doi: 10.1186/bcr3685.
Zotero 插件